市場概況

The GvHD treatment market was valued at USD 678.1 百万で 2022 and is projected to reach USD 1,039 百万までに 2029, CAGR は 6.0%. GvHD occurs when the donor’s T-cells attack the recipient’s healthy tissues after transplant procedures. The United States had the highest number of HSCTs, followed by China and Germany. The demand for allo-HSCT is growing due to increased incidence of leukemia and lymphoma, improved transplant success rates, and an aging population.

レポートは市場規模と成長をカバーしています, セグメンテーション, 競争環境, trends and strategies for global GvHD treatment market. 利害関係者が現在の市場機会を活用できるように、市場の定量的な分析を提供します。. このレポートはまた、市場動向と主要な競合他社のアプローチに基づいて、機会と戦略の上位セグメントを特定します。.

市場セグメンテーション

市場はさまざまな要因に基づいて分割されます, including drug class, treatment type, gender, そして地理.
Drug class: calcineurin inhibitors, corticosteroids, kinase inhibitors, TNF-alpha inhibitors, その他
Treatment type: acute GvHD, chronic GvHD, GvHD prophylaxis
Gender: females, males

地理によるセグメンテーション
North America – US
Europe – Germany, フランス, イギリス, イタリア, スペイン
アジア太平洋 – 中国, 日本

Corticosteroid drugs are projected to hold a significant share in the global GvHD treatment market, with kinase inhibitors expected to be the fastest-growing segment. Corticosteroids are commonly recommended as front-line therapy due to their safety and efficacy compared to alternative drugs. Acute GvHD is anticipated to contribute significantly to the market, affecting 30% に 50% of individuals undergoing stem cell transplantation. Males currently dominate the market, but females are projected to be the fastest-growing segment. The United States is currently dominant, but China is expected to exhibit faster growth. Factors driving the US market include increasing incidence of GvHD, presence of key players, and improved healthcare accessibility.

競争環境

Key players in the GvHD treatment market include AltruBio, 株式会社, ASC Therapeutics Inc., Bristol-Myers Squibb Company, Chia Tai-Tianqing Pharmaceutical Holdings Co., 株式会社, Elsalys Biotech SAS, Equillium, 株式会社, F. ホフマン・ラ・ロシュAG, Genentech, 株式会社, GSK plc, Incyte Corporation, Janssen Global Services, LLC, Jazz Pharmaceuticals plc, JCR Pharmaceuticals Co., 株式会社, Kadmon Corporation (Sanofi S.A.), MaaT Pharma SA, Mallinckrodt PLC, medac GmbH, Merck Corporation, Mesoblast Limited, MiNK Therapeutics, 株式会社, Neovii Pharmaceuticals AG, Novartis AG, Pharmacyclics LLC, Pluri Inc., REGiMMUNE Corporation, Sun Pharmaceutical Industries Ltd., Syndax Pharmaceuticals, 株式会社, Takeda Pharmaceutical Company Limited, Xenikos B.V., とりわけ.

報告書の範囲

To analyze and forecast the market size of the global GvHD treatment market.
To classify and forecast the global GvHD treatment market based on drug class, treatment type, gender, 地理.
To identify drivers and challenges for the global GvHD treatment market.
合併などの競争展開を検討するため & 買収, 協定, コラボレーションとパートナーシップ, 等, in the global GvHD treatment market.
To identify and analyze the profile of leading players operating in the global GvHD treatment market.

このレポートを選択する理由

Gain a reliable outlook of the global GvHD treatment market forecasts from 2023 に 2029 シナリオ全体にわたって.
投資対象となる成長セグメントを特定する.
会社概要と市場データを通じて競合他社に先んじる.
Excel 形式でのシナリオ全体の分析を容易にするための市場予測.
3ヶ月間の戦略コンサルティングとリサーチサポート.
シングルユーザーライセンスに提供される印刷認証.